Rasagiline mesylate

Rasagiline mesylate 구조식 이미지
카스 번호:
161735-79-1
상품명:
Rasagiline mesylate
동의어(영문):
Azilect;RASAGILINE MESILATE;RASAGILINE GLUCURONIDE;CS-289;TVP-101;Agilect;TV 1012;TVP-1012;Unii-lh8C2ji290;RASAGILINE MESYLATE
CBNumber:
CB7501001
분자식:
C13H17NO3S
포뮬러 무게:
267.34398
MOL 파일:
161735-79-1.mol
MSDS 파일:
SDS

Rasagiline mesylate 속성

녹는점
155-158°C
저장 조건
2-8°C
용해도
H2O: ≥20mg/mL
물리적 상태
가루
색상
흰색에서 황갈색까지
optical activity
[α]/D +15 to +28°, c = 0.6 mg/mL in H2O
안정성
제공된 대로 구매일로부터 2년 동안 안정적입니다. DMSO, 증류수 또는 에탄올에 용해된 용액은 -20°C에서 최대 1개월 동안 보관할 수 있습니다.
InChI
InChI=1/C12H13N.CH4O3S/c1-2-9-13-12-8-7-10-5-3-4-6-11(10)12;1-5(2,3)4/h1,3-6,12-13H,7-9H2;1H3,(H,2,3,4)/t12-;/s3
InChIKey
JDBJJCWRXSVHOQ-ZLBVLXFENA-N
SMILES
C12C=CC=CC=1CC[C@H]2NCC#C.S(C)(O)(=O)=O |&1:8,r|
CAS 데이터베이스
161735-79-1(CAS DataBase Reference)
안전
  • 위험 및 안전 성명
  • 위험 및 사전주의 사항 (GHS)
위험품 표기 Xn
위험 카페고리 넘버 22
안전지침서 24/25
WGK 독일 3
HS 번호 29214990
그림문자(GHS): GHS hazard pictograms
신호 어: Warning
유해·위험 문구:
암호 유해·위험 문구 위험 등급 범주 신호 어 그림 문자 P- 코드
H302 삼키면 유해함 급성 독성 물질 - 경구 구분 4 경고 GHS hazard pictograms P264, P270, P301+P312, P330, P501
예방조치문구:
P280 보호장갑/보호의/보안경/안면보호구를 착용하시오.
P305+P351+P338 눈에 묻으면 몇 분간 물로 조심해서 씻으시오. 가능하면 콘택트렌즈를 제거하시오. 계속 씻으시오.

Rasagiline mesylate C화학적 특성, 용도, 생산

개요

Rasagiline mesylate is a potent and selective irreversible monoamine oxidase B (MAO-B) inhibitor launched in 2005 in Israel by Teva as monotherapy in patients with early Parkinson's disease and as adjuvant treatment in moderate-toadvanced disease. Lundbeck will market the drug throughout Europe. Rasagiline is in phase II clinical trials at Teva and Eisai for the treatment of Alzheimer's type dementia.

화학적 성질

White to Off-White Crystalline Solid

용도

Rasagiline Mesylate is a new MAO-B inhibitor for the treatment of idiopathic Parkinson's disease.

Indications

Rasagiline mesylate is a novel, potent, second-generation, selective, irreversible MAO-B inhibitor that blocks the breakdown of dopamine. It is approved for the treatment of PD. Indications for use of once-daily rasagiline are as a monotherapy in early PD and as an adjunct to levodopa in moderate to advanced disease. Rasagiline significantly improves symptoms during initial monotherapy in patients with early PD and as an adjunct treatment to levodopa in moderate-to-advanced patients. Rasagiline is well tolerated up to doses as high as 20 mg/day. Evidence for neuroprotective effect of rasagiline is as follows (Jain 2010c):
Structure activity studies have shown that the neuroprotective activity is associated with the propargyl moiety of rasagiline, which protects mitochondrial viability.
Experimental evidence supports rasagiline's neuroprotective efficacy, showing that neuronal survival is related to the anti-apoptotic properties of its propargyl moiety. Aminoindan metabolite of rasagiline has been shown to have neuroprotective properties (Bar-Am et al. 2010).

일반 설명

Rasagiline mesylate, (R)-N-(prop-2-ynyl)-2,3-dihydro-1H-inden-1-amine methanesulfonate(Azilect), belongs to the propargylamine family and is a whiteto off-white powder, soluble in water or ethanol, slightly solublein isopropanol. Rasagiline is rapidly absorbed. Plasmaprotein binding for rasagiline ranges from 88% to 94%, withspecific binding to serum albumin being 61% to 63%. It undergoescomplete biotransformation before excretion, mainlyvia N-dealkylation and hydroxylation, to yield three majormetabolites: 1(R)-aminoindan, 3-hydroxy-N-propargyl-1-aminoindan, and 3-hydroxy-1-aminoindan. Both oxidativepathways are catalyzed by cytochrome P450 (CYP) enzymes,mainly the 1A2 isozyme. Rasagiline and its metabolites undergoglucuronide conjugation with subsequent urinary excretion.Inhibitors of the CYP1A2 may increase plasmaconcentrations of rasagiline up to twofold. Because rasagilineis a selective and irreversible inhibitor of MAO-B, itsduration of action is independent of the drug’s half-life and isinstead determined by the regeneration rate of MAO-B. Thischaracteristic is potentially beneficial in PD, where rasagiline’sprolonged effect may be able to limit the fluctuating responsesthat are characteristic of long-term drug treatmentwith levodopa.

Mechanism of action

The specific mechanism of action of Rasagiline mesylate is unknown. One of these mechanisms is thought to be related to its MAO-B inhibitory activity, which leads to elevated extracellular dopamine levels in the striatum. It irreversibly blocks dopamine metabolism, thereby increasing dopamine levels, which can be beneficial for symptoms in Parkinson's disease patients.

Rasagiline mesylate 준비 용품 및 원자재

원자재

준비 용품


Rasagiline mesylate 공급 업체

글로벌( 378)공급 업체
공급자 전화 이메일 국가 제품 수 이점
TAIZHOU YUXIN BIOTECHNOLOGY CO,.LTD
+86-576-88902229;+86-0576-88902229 +8613968687450
yuxin@yuxchem.com China 122 58
Shanghai Daken Advanced Materials Co.,Ltd
+86-371-66670886
info@dakenam.com China 15371 58
Beijing Cooperate Pharmaceutical Co.,Ltd
010-60279497
sales01@cooperate-pharm.com CHINA 1811 55
Henan Tianfu Chemical Co.,Ltd.
+86-0371-55170693 +86-19937530512
info@tianfuchem.com China 21695 55
ATK CHEMICAL COMPANY LIMITED
+undefined-21-51877795
ivan@atkchemical.com China 32480 60
career henan chemical co
+86-0371-86658258
sales@coreychem.com China 29914 58
Biochempartner
0086-13720134139
candy@biochempartner.com CHINA 967 58
Accela ChemBio Inc.
(+1)-858-699-3322
info@accelachem.com United States 19965 58
Xiamen AmoyChem Co., Ltd
+86-592-6051114 +8618959220845
sales@amoychem.com China 6387 58
BOC Sciences
+1-631-485-4226
inquiry@bocsci.com United States 19553 58

Rasagiline mesylate 관련 검색:

Copyright 2019 © ChemicalBook. All rights reserved